Sanofi S.A. ADS

  • TickerSNYN
  • ISINUS80105N1054
  • ExchangeMexican Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Sanofi: Update following publication of Q3 results

Our credit view of Sanofi, reflecting its diversified business profile and still-large cash position following the sale of its Regeneron shares.

Sanofi: Financial flexibility for mid-sized acquisitions remains after tender offer on Principia

Sanofi will finance this acquisition with the excess cash position it built with the sale of its stake in Regeneron.

Moody's announces completion of a periodic review of ratings of Sanofi

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Sanofi. Global Credit Research- 11 Aug 2020. Paris, August 11, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Sanofi and other ratings that are associated with the same analytical unit.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Encouraging Signs, But Not Out Of The Woods Positive news flow surrounding COVID-19 is encouraging on many fronts, and we welcome headlines such as peaking infections/deaths in Italy & Spain, certain European governments making plans to ease lockdowns, and that US death projections were likely overestimated. Despite encouraging news and the S&P 500 (SPX) hitting multi-week highs, market signals continue to suggest that this is a fairly standard bear market rally, making us believe the broad equity market is not yet out of the woods and remains vulnerable. · S&P 500 Levels. Short-ter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Sanofi: Update following publication of Q3 results

Our credit view of Sanofi, reflecting its diversified business profile and still-large cash position following the sale of its Regeneron shares.

Sanofi: Financial flexibility for mid-sized acquisitions remains after tender offer on Principia

Sanofi will finance this acquisition with the excess cash position it built with the sale of its stake in Regeneron.

Moody's announces completion of a periodic review of ratings of Sanofi

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Sanofi. Global Credit Research- 11 Aug 2020. Paris, August 11, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Sanofi and other ratings that are associated with the same analytical unit.

Sanofi: Update following rating affirmation

Our credit view of Sanofi, reflecting its strong and diversified business profile and our expectation that its credit ratios will improve over the next 18 months.

Moody's affirms Sanofi's A1 ratings following the sale of its stake in Regeneron

Rating Action: Moody's affirms Sanofi's A1 ratings following the sale of its stake in Regeneron. Global Credit Research- 02 Jun 2020. Paris, June 02, 2020-- Moody's Investors Service, has today affirmed the A1 long-term ratings of France-based pharmaceutical company Sanofi and its guaranteed subsidiary Genzyme Corporation.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch